Early Phase Clinical Studies Update

Total Page：16

File Type：pdf, Size：1020Kb

Early Phase and/or Targeted Therapy Studies in Pediatric Oncology in Switzerland Study Agent(s) Phase Indication Age Open Sites Contact / PI BEACON ± Dinutuximab beta (rando 2b Neuroblastoma (relapsed or refractory) 1-21y Zürich, Nicolas Gerber 2:+ with possibility of cross- Lausanne Maja Beck-Popovic over) + backbone with TMZ, or TMZ+topotecan (rando) T-VEC Talimogene laherparepvec 1 Relapsed or refractory solid (non-CNS 0-21y Zürich, Felix Niggli (oncolytic virus) tumors) with at least 1 injectable (non- Basel Thomas Kühne visceral) lesion Venetoclax Venetoclax 1 Relapsed or refractory tumors: solid tumors 0-25y Zürich Nicolas Gerber with BCL-2 expression and AML/ALL/lymphoma Dabrafenib/ Dabrafenib and Trametinib 2 High-grade glioma (BRAF V600 mutation 6-18y Zürich Nicolas Gerber Trametinib positive, relapsed or refractory), Low Grade Glioma (BRAF V600 mutation positive, unresectable tumor requiring treatment: for LGG only as first non-surgical treatment) Larotrectinib Larotrectinib 1/2 Advanced solid tumors (CNS and Non-CNS) 0-21y (incl. of Zürich Nicolas Gerber (Phase 1 expansion cohort and Phase 2: older pat. with NTRK gene fusion required [or for infantile ped. tumor fibrosarcoma, congenital mesoblastic types to be Solid Tumors Solid nephroma, or secretory breast cancer: discussed with ETV6 rearrangement]. Phase II: also benign sponsor) tumors with NTRK fusion eligible) Claudia Althaus, Clinical Trials Manager ([email protected]) University Children's Hospital, Zürich Nicolas Gerber, Ped. Oncologist ([email protected]) 19 Dec 2019 Page 1 / 2 Solid Tumors Solid Fimepinostat Fimepinostat (start 2 days 1 Newly Diagnosed Diffuse Intrinsic Pontine 3-39y Zürich Nicolas Gerber before biopsy/surgery!) Glioma (DIPG), Recurrent Medulloblastoma, or Recurrent High-Grade Glioma (HGG). Fimepinostat is started 2 days before biopsy/tumor surgery. Target valiation in tumor tissue. Cont. therapy (after RT in DIPG, after biopsy/surgery in others) Eribulin Eribulin Mesilate + 2 refractory or recurrent RMS or NRSTS 1-18y Zürich (in Nicolas Gerber Irinotecan prep.) OLIE +- Lenvatinib (rando), 2 refractory or relapsed osteosarcoma 2-25y Zürich (in Nicolas Gerber Backbone prep.) Ifosfamide/Etoposid Bchild Bosutinib 1/2 CML (resistant or intolarant to at least one 1-18y Zürich Jean-Pierre Bourquin prior Tyrosine Kinase Inhibitor) Inotuzumab Inotuzumab Ozogamicin 1/2 relapsed/refractory CD22 positive B-cell 1-18y Zürich Jean-Pierre Bourquin precursor (BCP)-ALL or other CD22 positive B-cell malignancies Venetoclax Venetoclax 1 Relapsed or refractory tumors: 0-25y Zürich Nicolas Gerber AML/ALL/lymphoma, and solid tumors with Leukemia/lymphoma BCL-2 expression NEW: primary therapy of TCF3-HLF ALL Emapalumab Emapalumab (Anti-INFy 3 Primary Hemaphagocytic 0-18y Zürich Jana Pachlopnik Antibody) Lymphohistiocytosis Other REACH 5 Ruxolitinib 2 Moderate and severe cGvHD after SCT 0-18y Zürich (in Tayfun Güngör prep.) Further studies in preparation Claudia Althaus, Clinical Trials Manager ([email protected]) University Children's Hospital, Zürich Nicolas Gerber, Ped. Oncologist ([email protected]) 19 Dec 2019 Page 2 / 2.

Copy Link

Recommended publications

Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients
antibodies Review Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients Andrew T. Lucas 1,2,3,*, Ryan Robinson 3, Allison N. Schorzman 2, Joseph A. Piscitelli 1, Juan F. Razo 1 and William C. Zamboni 1,2,3 1 University of North Carolina (UNC), Eshelman School of Pharmacy, Chapel Hill, NC 27599, USA; [email protected] (J.A.P.); [email protected] (J.F.R.); [email protected] (W.C.Z.) 2 Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; [email protected] 3 Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-919-966-5242; Fax: +1-919-966-5863 Received: 30 November 2018; Accepted: 22 December 2018; Published: 1 January 2019 Abstract: The rapid advancement in the development of therapeutic proteins, including monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs), has created a novel mechanism to selectively deliver highly potent cytotoxic agents in the treatment of cancer. These agents provide numerous beneﬁts compared to traditional small molecule drugs, though their clinical use still requires optimization. The pharmacology of mAbs/ADCs is complex and because ADCs are comprised of multiple components, individual agent characteristics and patient variables can affect their disposition. To further improve the clinical use and rational development of these agents, it is imperative to comprehend the complex mechanisms employed by antibody-based agents in traversing numerous biological barriers and how agent/patient factors affect tumor delivery, toxicities, efﬁcacy, and ultimately, biodistribution.
[Show full text]
Dinutuximab for the Treatment of Pediatric Patients with High-Risk Neuroblastoma
Expert Review of Clinical Pharmacology ISSN: 1751-2433 (Print) 1751-2441 (Online) Journal homepage: http://www.tandfonline.com/loi/ierj20 Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma Jaume Mora To cite this article: Jaume Mora (2016): Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma, Expert Review of Clinical Pharmacology, DOI: 10.1586/17512433.2016.1160775 To link to this article: http://dx.doi.org/10.1586/17512433.2016.1160775 Accepted author version posted online: 02 Mar 2016. Published online: 21 Mar 2016. Submit your article to this journal Article views: 21 View related articles View Crossmark data Full Terms & Conditions of access and use can be found at http://www.tandfonline.com/action/journalInformation?journalCode=ierj20 Download by: [Hospital Sant Joan de Deu], [Jaume Mora] Date: 30 March 2016, At: 23:12 EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016 http://dx.doi.org/10.1586/17512433.2016.1160775 DRUG PROFILE Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma Jaume Mora Department of Pediatric Onco-Hematology and Developmental Tumor Biology Laboratory, Hospital Sant Joan de Déu, Passeig Sant Joan de Déu, Barcelona, Spain ABSTRACT ARTICLE HISTORY Neuroblastoma (NB) is the most common extra cranial solid tumor of childhood, with 60% of patients Received 14 December 2015 presenting with high risk (HR) NB by means of clinical, pathological and biological features. The 5-year Accepted 29 February 2016 survival rate for HR-NB remains below 40%, with the majority of patients suffering relapse from Published online chemorefractory tumor. Immunotherapy is the main strategy against minimal residual disease and 21 March 2016 clinical experience has mostly focused on monoclonal antibodies (MoAb) against the glycolipid dis- KEYWORDS ialoganglioside GD2.
[Show full text]
Chemotherapeutic Agents for Brain Metastases in Non-Small Cell Lung
Fuentes et al. Clin Med Rev Case Rep 2016, 3:107 Volume 3 | Issue 5 Clinical Medical Reviews ISSN: 2378-3656 and Case Reports Case Report: Open Access Chemotherapeutic Agents for Brain Metastases in Non-Small Cell Lung Cancer: A Case Report with Eribulin Mesylate and Review of the Literature Alejandra C Fuentes1, Reordan O De Jesus2 and David N Reisman3* 1Department of Internal Medicine, University of Florida, Gainesville, FL, USA 2Department of Radiology, University of Florida, Gainesville, FL, USA 3Department of Medicine, Division of Hematology/Oncology, University of Florida, Gainesville, FL, USA *Corresponding author: David N Reisman M.D., Ph.D, Department of Medicine, Division of Hematology/ Oncology, University of Florida, PO Box 100278, Gainesville, FL 32610-0278, USA, Tel: 352-273-7832, E-mail: [email protected] nervous system (CNS), where systemic chemotherapy has had poor Abstract penetration. Lung cancer accounts for the majority of cases of brain metastases, resulting in higher morbidity and mortality. Surgery and radiation are The standard treatment options for BM include surgical resection the current standard of care for the treatment of brain metastases. or stereotactic radio surgery (SRS) for patients with a limited number However, when brain metastases recur despite these treatments, of lesions (3-4), and whole brain radiation therapy (WBRT) for the management options are limited, especially when recurrent multiple lesions. What has not been well defined in the treatment of metastatic events occur. The role of systemic chemotherapy BM is the role of systemic chemotherapy [5]. Systemic chemotherapy for brain metastases remains undefined, with advances in drug has been found in some evidence-based studies to show no survival delivery and ongoing studies using targeted agents showing benefit in the treatment of BM [5,6].
[Show full text]
HALAVEN™ Safely and Effectively
HIGHLIGHTS OF PRESCRIBING INFORMATION ----------------WARNINGS AND PRECAUTIONS---------- These highlights do not include all the information needed to use • Neutropenia: Monitor peripheral blood cell counts and adjust HALAVEN™ safely and effectively. See full prescribing dose as appropriate (2.2, 5.1, 6). information for HALAVEN. • Peripheral Neuropathy: Monitor for signs of neuropathy. HALAVEN™ (eribulin mesylate) Injection Manage with dose delay and adjustment (2.2, 5.2, 6). For intravenous administration only. • Use in Pregnancy: Fetal harm can occur when administered to Eisai Inc. a pregnant woman (5.3) (8.1). Initial US Approval: 2010 • QT Prolongation: Monitor for prolonged QT intervals in patients with congestive heart failure, bradyarrhythmias, drugs ------------------INDICATIONS AND USAGE----------------- known to prolong the QT interval, and electrolyte • HALAVEN is a microtubule inhibitor indicated for the abnormalities. Avoid in patients with congenital long QT treatment of patients with metastatic breast cancer who have syndrome (5.4). previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the ----------------------ADVERSE REACTIONS------------------ adjuvant or metastatic setting (1). The most common adverse reactions (incidence ≥25%) were neutropenia, anemia, asthenia/fatigue, alopecia, peripheral neuropathy, nausea, and constipation (6). --------------DOSAGE AND ADMINISTRATION------------ • Administer 1.4 mg/m2 intravenously over 2 to 5 minutes on To report SUSPECTED ADVERSE REACTIONS, contact Days 1 and 8 of a 21-day cycle (2.1). Eisai Inc. at (1-877-873-4724) or contact FDA at 1-800-FDA- • Reduce dose in patients with hepatic impairment and moderate 1088 or www.fda.gov/medwatch renal impairment (2.1).
[Show full text]
Federal Register Notice 5-1-2020 Pdf Icon[PDF – 358
Federal Register / Vol. 85, No. 85 / Friday, May 1, 2020 / Notices 25439 confidential by the respondent (5 U.S.C. schedules. Other than examination DEPARTMENT OF HEALTH AND 552(b)(4)). reports, it provides the only financial HUMAN SERVICES Current actions: The Board has data available for these corporations. temporarily revised the instructions to The Federal Reserve is solely Centers for Disease Control and the FR Y–9C report to accurately reflect responsible for authorizing, supervising, Prevention the revised definition of ‘‘savings and assigning ratings to Edges. The [CDC–2020–0046; NIOSH–233–C] deposits’’ in accordance with the Federal Reserve uses the data collected amendments to Regulation D in the on the FR 2886b to identify present and Hazardous Drugs: Draft NIOSH List of interim final rule published on April 28, potential problems and monitor and Hazardous Drugs in Healthcare 2020 (85 FR 23445). Specifically, the develop a better understanding of Settings, 2020; Procedures; and Risk Board has temporarily revised the activities within the industry. Management Information instructions on the FR Y–9C, Schedule HC–E, items 1(b), 1(c), 2(c) and glossary Legal authorization and AGENCY: Centers for Disease Control and content to remove the transfer or confidentiality: Sections 25 and 25A of Prevention, HHS. withdrawal limit. As a result of the the Federal Reserve Act authorize the ACTION: Notice and request for comment. revision, if a depository institution Federal Reserve to collect the FR 2886b chooses to suspend enforcement of the (12 U.S.C. 602, 625). The obligation to SUMMARY: The National Institute for six transfer limit on a ‘‘savings deposit,’’ report this information is mandatory.
[Show full text]
And Grand Overview
Welcome and Grand Overview Rose Aurigemma, PhD Acting Associate Director, Developmental Therapeutics Program Division of Cancer Treatment & Diagnosis, NCI July 23, 2021 Thank You to the Organizing Committee Weiwei Chen, Program Director, PTGB, DTP Rachelle Salomon, Program Director, BRB, DTP Sharad Verma, Program Director, PTGB, DTP Jason Yovandich, Chief, BRB, DTP Sundar Venkatachalam, Chief, PTGB, DTP 2 Introduction to the Developmental Therapeutics Program In 1955, congress created the Cancer Chemotherapy National Service Center which evolved, both structurally and functionally, into today’s Developmental Therapeutics Program (DTP). DTP’s involvement in the discovery or development of many anticancer therapeutics on the market today demonstrates its indelible impact on efforts to improve the health and well-being of people with cancer. 3 Approved Cancer Therapies with DTP Assistance 2018 Moxetumomab pasudotox-tdfk 1983 Etoposide (NSC 141540) 2015 Dinutuximab (Unituxin, NSC 764038) 1982 Streptozotocin (NSC 85998) Ecteinascidin 743 (NSC 648766) 1979 Daunorubicin (NSC 82151) 2012 Omacetaxine (homoharringtonine, NSC 141633) 1978 Cisplatin (cis-platinum) (NSC 119875) 2010 Eribulin (NSC 707389) 1977 Carmustine (BCNU) (NSC 409962) Sipuleucel-T (NSC 720270) 1976 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosurea (CCNU) 2009 Romidepsin (NSC 630176) (NSC 9037) Pralatrexate (NSC 713204) 1975 Dacarbazine (NSC 45388) 2004 Azacitidine (NSC 102816) 1974 Doxorubicin (NSC 123127) Cetuximab (NSC 632307) Mitomycin C (NSC 26980) 2003 Bortezomib (NSC 681239) 1973
[Show full text]
BC Cancer Benefit Drug List September 2021
Page 1 of 65 BC Cancer Benefit Drug List September 2021 DEFINITIONS Class I Reimbursed for active cancer or approved treatment or approved indication only. Reimbursed for approved indications only. Completion of the BC Cancer Compassionate Access Program Application (formerly Undesignated Indication Form) is necessary to Restricted Funding (R) provide the appropriate clinical information for each patient. NOTES 1. BC Cancer will reimburse, to the Communities Oncology Network hospital pharmacy, the actual acquisition cost of a Benefit Drug, up to the maximum price as determined by BC Cancer, based on the current brand and contract price. Please contact the OSCAR Hotline at 1-888-355-0355 if more information is required. 2. Not Otherwise Specified (NOS) code only applicable to Class I drugs where indicated. 3. Intrahepatic use of chemotherapy drugs is not reimbursable unless specified. 4. For queries regarding other indications not specified, please contact the BC Cancer Compassionate Access Program Office at 604.877.6000 x 6277 or [email protected] DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES Therapy for Metastatic Castration-Sensitive Prostate Cancer using abiraterone tablet Genitourinary UGUMCSPABI* R Abiraterone and Prednisone Palliative Therapy for Metastatic Castration Resistant Prostate Cancer abiraterone tablet Genitourinary UGUPABI R Using Abiraterone and prednisone acitretin capsule Lymphoma reversal of early dysplastic and neoplastic stem changes LYNOS I first-line treatment of epidermal
[Show full text]
1826 ALL FINAL 2[2].Pptx
7/17/18 Treatment Challenges in Acute Lymphoblastic Leukemia Pharmacists’ Key Roles in Ensuring Best Practices This educational activity is sponsored by Postgraduate Healthcare Education, LLC and supported by an educational grant from Pfizer. 1 7/17/18 Faculty Christopher A. Fausel, PharmD, MHA, BCOP Clinical Manager, Oncology Pharmacy Indiana University Health Chairman, Hoosier Cancer Research Network Indianapolis, Indiana Dr. Fausel is the Clinical Manager of the Oncology Pharmacy at the Indiana University, Simon Cancer Center in Indianapolis and oversees clinical and dispensing activities for oncology pharmacy services at Indiana University Health. He also serves as Chairman of the Board of the Hoosier Cancer Research Network, a non-profit organization that conducts clinical trials and translational research in cancer and is the administrative center of the Big Ten Cancer Research Consortium. Dr. Fausel is the Chair of a biomedical IRB and serves on the IRB Executive Committee for Indiana University. He is a long standing member of ASHP, ASCO and HOPA. He has authored numerous academic writings and is a nationally invited speaker on topics of oncology therapeutics and oncology pharmacy practice. Disclosures Dr. Fausel has no relevant affiliations or financial relationships with a commercial interest to disclose. The clinical reviewer, Megan May, PharmD, BCOP, has no actual or potential conflict of interest in relation to this program. Susanne Batesko, RN, BSN, Robin Soboti, RPh, and Susan R. Grady, MSN, RN-BC, as well as the planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of Postgraduate Healthcare Education (PHE) continuing education activities hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months to disclose in relation to this activity.
[Show full text]
Update in Pediatric Oncology Pediatric Leukemia
9/21/2016 Objectives • Review newest therapies in pediatric oncology • Discuss the use of Blinatumomab in pediatric Update in Pediatric Oncology patients • Review Car T‐Cell immunotherapy in pediatric Katie Bruce, PharmD, BCPPS patients Pharmacy Clinical Specialist • Discuss the latest therapy approved for use in Pediatric Oncology and BMT The Children’s Hospital at TriStar neuroblastoma Centennial Disclosure • I have no financial conflicts to disclose Pediatric Leukemia Pediatric Leukemia Classification • Acute lymphoblastic leukemia (ALL) is the most • Over 85% of childhood ALL is B‐cell ALL common cancer in children ▫ Most commonly precursor‐B cell ALL ▫ Accounts for ~30% of all cancers 2% mature B‐cell ALL ▫ 3000 new cases in US each year ▫ 15% T‐cell ALL (Birth –21 years old) Investigating use of nelarabine and/or high dose methotrexate ~ 80% are ALL and ~20% are AML ▫ Incidence of 3.4 cases per 100,000 • Risk Criteria ▫ Most common between 2 and 5 years old ▫ Initial WBC count ▫ Boys > girls ▫ Age • Higher incidence in Caucasians and Hispanics vs. African ▫ Cytogenetics American Children ▫ Immunologic subtype www.curesearch.org www.curesearch.org 1 9/21/2016 Risk Stratification Outcomes • ~85% overall 5‐year event‐free survival ▫ 90 –95 % in low‐ or standard‐risk pre‐B ALL with good response to induction chemotherapy ▫ 75 –85 % in high‐risk with good early response ▫ <75% in very high‐risk (Ph+, hypodiploid, CNS3) or slow response to chemo • T‐cell ALL survival lower at 70 –75 % • Infant ALL ▫ Poor prognosis with 10‐30% event‐free
[Show full text]
Inotuzumab Ozogamicin) for Injection, for Intravenous Use for Injection: 0.9 Mg Lyophilized Powder in a Single-Dose Vial for Initial U.S
HIGHLIGHTS OF PRESCRIBING INFORMATION • See full prescribing information for instructions on reconstitution of These highlights do not include all the information needed to use lyophilized powder, and preparation and administration of reconstituted BESPONSA™ safely and effectively. See full prescribing information for drug. (2.4) BESPONSA. --------------------- DOSAGE FORMS AND STRENGTHS--------------------- BESPONSA (inotuzumab ozogamicin) for injection, for intravenous use For injection: 0.9 mg lyophilized powder in a single-dose vial for Initial U.S. Approval: 2017 reconstitution and further dilution. (3) WARNING: HEPATOTOXICITY, INCLUDING HEPATIC VENO ------------------------------ CONTRAINDICATIONS ----------------------------- OCCLUSIVE DISEASE (VOD) (ALSO KNOWN AS SINUSOIDAL None (4) OBSTRUCTION SYNDROME and INCREASED RISK OF POST HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) NON ----------------------- WARNINGS AND PRECAUTIONS ---------------------- RELAPSE MORTALITY • Myelosuppression: Monitor complete blood counts; for signs and See full prescribing information for complete boxed warning. symptoms of infection; bleeding/hemorrhage; or other effects of myelosuppression during treatment; manage appropriately. (5.3) • Hepatotoxicity, including fatal and life-threatening VOD occurred in • Infusion related reactions: Monitor for infusion related reactions during and patients who received BESPONSA. (5.1) for at least 1 hour after infusion ends. (5.4) • A higher post-HSCT non-relapse mortality rate occurred in patients • QT interval
[Show full text]
Qarziba, INN-Dinutuximab Beta
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions. 1. NAME OF THE MEDICINAL PRODUCT Qarziba 4.5 mg/mL concentrate for solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 mL of concentrate contains 4.5 mg dinutuximab beta. Each vial contains 20 mg dinutuximab beta in 4.5 mL. Dinutuximab beta is a mouse-human chimeric monoclonal IgG1 antibody produced in a mammalian cell line (CHO) by recombinant DNA technology. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Concentrate for solution for infusion Clear, colourless liquid. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Qarziba is indicated for the treatment of high-risk neuroblastoma in patients aged 12 months and above, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and stem cell transplantation, as well as patients with history of relapsed or refractory neuroblastoma, with or without residual disease. Prior to the treatment of relapsed neuroblastoma, any actively progressing disease should be stabilised by other suitable measures. In patients with a history of relapsed/refractory disease and in patients who have not achieved a complete response after first line therapy, Qarziba should be combined with interleukin-2 (IL-2). 4.2 Posology and method of administration Qarziba is restricted to hospital-use only and must be administered under the supervision of a physician experienced in the use of oncological therapies.
[Show full text]
Insensitive Tumor Cells
Global Journal of Cancer Therapy eertechz Richard J Rickles1, Junji Matsui3, Ping Research Article Zhu1, Yasuhiro Funahashi2,3, Jill M Grenier1, Janine Steiger1, Nanding Zhao2, Bruce A Littlefield2, Kenichi Identification of Combinatorial Nomoto2,3 and Toshimitsu Uenaka2* 1Horizon Discovery Inc., MA, Japan Drugs that Synergistically Kill both 2Eisai Inc., MA, Japan 3Eisai Co., Ltd., Japan Eribulin-Sensitive and Eribulin- Dates: Received: 17 October, 2015; Accepted: 03 November, 2015; Published: 04 November, 2015 Insensitive Tumor Cells *Corresponding author: Toshimitsu Uenaka, Ph.D., Executive Director, Production Creation Headquarter, Oncology & Antibody Drug Strategy, CINO (Chief Abstract Innovation Officer), E-mail: Eribulin sensitivity was examined in a panel of twenty-five human cancer cell lines representing a www.peertechz.com variety of tumor types, with a preponderance of breast and lung cancer cell lines. As expected, the cell lines vary in sensitivity to eribulin at clinically relevant concentrations. To identify combination drugs capable of increasing anticancer effects in patients already responsive to eribulin, as well as inducing de novo anticancer effects in non-responders, we performed a combinatorial high throughput screen to identify drugs that combine with eribulin to selectively kill tumor cells. Among other observations, we found that inhibitors of ErbB1/ErbB2 (lapatinib, BIBW-2992, erlotinib), MEK (E6201, trametinib), PI3K (BKM-120), mTOR (AZD 8055, everolimus), PI3K/mTOR (BEZ 235), and a BCL2 family antagonist (ABT-263) show combinatorial activity with eribulin. In addition, antagonistic pairings with other agents, such as a topoisomerase I inhibitor (topotecan hydrochloride), an HSP-90 inhibitor (17-DMAG), and gemcitabine and cytarabine, were identified. In summary, the preclinical studies described here have identified several combination drugs that have the potential to either augment or antagonize eribulin’s anticancer activity.
[Show full text]